2894679.mp4

Trapping and moving a 5-um yeast cell by the fiber tip with the second taper angle of 48 deg. The trapping power is 20 mW

Graphene Oxide/Chitosan Aerogel Microspheres with Honeycomb-Cobweb and Radially Oriented Microchannel Structures for Broad-Spectrum and Rapid Adsorption of Water Contaminants

Multifunctional graphene oxide (GO)/chitosan (CS) aerogel microspheres (GCAMs) with honeycomb-cobweb and radially oriented microchannel structures are prepared by combining electrospraying with freeze-casting to optimize adsorption performances of heavy metal ions and soluble organic pollutants. The GCAMs exhibit superior adsorption capacities of heavy metal ions of Pb­(II), Cu­(II), and Cr­(VI), cationic dyes of methylene blue (MB) and Rhodamine B, anionic dyes of methyl orange and Eosin Y, and phenol. It takes only 5 min to reach 82 and 89% of equilibrium adsorption capacities for Cr­(VI) (292.8 mg g^–1) and MB (584.6 mg g^–1), respectively, much shorter than the adsorption equilibrium time (75 h) of a GO/CS monolith. More importantly, the GCAMs maintain excellent adsorption capacity for six cycles of adsorption–desorption. The broad-spectrum, rapid, and reusable adsorption performance makes the GCAMs promising for highly efficient water treatments

Efficient Photocatalytic Reduction Approach for Synthesizing Chemically Bonded N‑Doped TiO₂/Reduced Graphene Oxide Hybrid as a Freestanding Electrode for High-Performance Lithium Storage

Covalent bonds between active materials and conductive substrates significantly facilitate rapid interfacial charge transfer, thus enhancing the lithium-ion storage performances of freestanding electrodes. Herein, an efficient photocatalytic reduction approach is developed to synthesize chemically bonded N-doped TiO₂ nanowire/reduced graphene oxide (N-TiO₂/RGO) hybrid as a freestanding electrode for ultrafast lithium storage. Ti³⁺–C bonds are formed during the ultraviolet photocatalytic reduction process, as corroborated by Raman, electron paramagnetic resonance, and X-ray photoelectron spectra. The N-TiO₂/RGO hybrid electrode exhibits a significantly higher rate capability than its counterpart without UV irradiation. After as long as 10,000 discharging/charging cycles, high capacities of 182.7, 125.1, and 101.8 mA h g^–1 are retained at current rates of 5, 25, and even up to 50 C (1 C = 335 mA g^–1), respectively. The excellent electrochemical performances of the N-TiO₂/RGO hybrid are attributed to the enhanced electronic conductivity and lithium-ion diffusion kinetics arising from the Ti³⁺–C bonds and the robust architecture of N-doped TiO₂

Tetrahedral Silver Phosphate/Graphene Oxide Hybrids as Highly Efficient Visible Light Photocatalysts with Excellent Cyclic Stability

The degradation efficiency and recyclability of photocatalysts are the key for their practical applications. Tetrahedral silver phosphate (Ag₃PO₄) is a superior visible-light photocatalyst, while graphene oxide (GO) sheets with high specific surface area and abundant functional groups are expected to further enhance the photocatalytic efficiency and improve the recyclability of Ag₃PO₄. Herein, we demonstrate an eco-friendly and kinetically controlled approach to synthesize Ag₃PO₄/GO hybrids. Tetrahedral Ag₃PO₄ are grown in situ on the GO sheets in mixed solvents, and their microstructures are controlled by the slow dissolution and ionization of H₃PO₄ and the adjustment of the volume ratios of ethanol/water solvents. The hybrid with 5 wt % of GO exhibits an extraordinary photocatalytic efficiency and satisfactory recyclability for the degradation of organic dyes. Approximately 99% of methylene blue could be degraded in 4 min, and the degradation percentage is still as high as 97% even after 5 cycles of photocatalytic degradations. The mechanism of reinforcement of the photocatalytic performance was also studied. This hybridization of tetrahedral Ag₃PO₄ with GO sheets provides an efficient solution to the photocorrosion of Ag₃PO₄ and is an efficient approach for synthesizing Ag₃PO₄-based semiconducting hybrids as highly efficient and recyclable photocatalysts

Image1_Mid-term scheduling and trading decisions for cascade hydropower stations considering multiple variable uncertainties.jpg

Cascade hydropower producers face two stages of risk when participating in medium and long-term market transactions: transaction risk during the bidding stage; and the operational risk during the scheduling and operation stage due to the uncertainty of runoff and market-clearing prices. Therefore, how to measure the above risks and make corresponding decisions has become an urgent problem for producers.This paper combines the real market structure and rules of a certain hydropower dominated market in Southwest China, and establishes a mid-term operation and trading decision-making method based on the Joint Information Gap Decision Theory (IGDT) and Prospect Theory. To address the main uncertainty variables that producers face in participating in transactions, this paper obtains the maximum fluctuation range of variables that satisfy the expected revenue in a robust model based on IGDT. Then, using Prospect Theory, a bidding strategy model that takes into account the psychological factors of producers is constructed within this range.To solve the nonlinear programming problem and address the accuracy issues caused by curve fitting during the solution process, a nonlinear programming combined with an improved stepwise optimization hybrid algorithm is employed.Using actual data from a hydropower grid in southwest China participating in the market as an example. The results indicate that the method provides the fluctuation range of runoff and market prices under different expected return targets, and can formulate reasonable bidding decisions and operation plans based on producers different risk preferences within this range.</p

DataSheet1_Mid-term scheduling and trading decisions for cascade hydropower stations considering multiple variable uncertainties.docx

Cascade hydropower producers face two stages of risk when participating in medium and long-term market transactions: transaction risk during the bidding stage; and the operational risk during the scheduling and operation stage due to the uncertainty of runoff and market-clearing prices. Therefore, how to measure the above risks and make corresponding decisions has become an urgent problem for producers.This paper combines the real market structure and rules of a certain hydropower dominated market in Southwest China, and establishes a mid-term operation and trading decision-making method based on the Joint Information Gap Decision Theory (IGDT) and Prospect Theory. To address the main uncertainty variables that producers face in participating in transactions, this paper obtains the maximum fluctuation range of variables that satisfy the expected revenue in a robust model based on IGDT. Then, using Prospect Theory, a bidding strategy model that takes into account the psychological factors of producers is constructed within this range.To solve the nonlinear programming problem and address the accuracy issues caused by curve fitting during the solution process, a nonlinear programming combined with an improved stepwise optimization hybrid algorithm is employed.Using actual data from a hydropower grid in southwest China participating in the market as an example. The results indicate that the method provides the fluctuation range of runoff and market prices under different expected return targets, and can formulate reasonable bidding decisions and operation plans based on producers different risk preferences within this range.</p

Image7_HER2 status of CTCs by peptide-functionalized nanoparticles as the diagnostic biomarker of breast cancer and predicting the efficacy of anti-HER2 treatment.TIF

Efficacy of anti-human epidermal growth factor receptor 2 (HER2) treatment is impacted by tissue-based evaluation bias due to tumor heterogeneity and dynamic changes of HER2 in breast cancer. Circulating tumor cell (CTC)-based HER2 phenotyping provides integral and real-time assessment, benefiting accurate HER2 diagnosis. This study developed a semi-quantitative fluorescent evaluation system of HER2 immunostaining on CTCs by peptide-functionalized magnetic nanoparticles (Pep@MNPs) and immunocytochemistry (ICC). 52 newly-diagnosed advanced breast cancer patients were enrolled for blood samples before and/or after first-line treatment, including 24 patients who were diagnosed with HER2+ tumors and treated with anti-HER2 drugs. We enumerated CTCs and assessed levels of HER2 expression on CTCs in 2.0 ml whole blood. Enumerating CTCs at baseline could distinguish cancer patients (sensitivity, 69.2%; specificity, 100%). 80.8% (42/52) of patients had at least one CTCs before therapy. Patients with <3 CTCs at baseline had significantly longer progression-free survival (medians, 19.4 vs. 9.2 months; log-rank p = 0.046) and overall survival (medians, not yet reached; log-rank p = 0.049) than those with ≥3 CTCs. Both HER2+ and HER2-low patients could be detected with HER2 overexpression on CTCs (CTC-HER2+) (52.6%, 44.4%, respectively), whereas all the HER2-negative patients had no CTC-HER2+ phenotype. Among HER2+ patients with ≥3 CTCs at baseline, objective response only appeared in pretherapeutic CTC-HER2+ cohort (60.0%), rather than in CTC-HER2– cohort (0.0%) (p = 0.034). In conclusion, we demonstrate the significance of CTC enumeration in diagnosis and prognosis of first-line advanced breast cancer, and highlight the value of CTC-HER2 status in predicting efficacy of anti-HER2 treatment.</p

Image6_HER2 status of CTCs by peptide-functionalized nanoparticles as the diagnostic biomarker of breast cancer and predicting the efficacy of anti-HER2 treatment.TIF

Efficacy of anti-human epidermal growth factor receptor 2 (HER2) treatment is impacted by tissue-based evaluation bias due to tumor heterogeneity and dynamic changes of HER2 in breast cancer. Circulating tumor cell (CTC)-based HER2 phenotyping provides integral and real-time assessment, benefiting accurate HER2 diagnosis. This study developed a semi-quantitative fluorescent evaluation system of HER2 immunostaining on CTCs by peptide-functionalized magnetic nanoparticles (Pep@MNPs) and immunocytochemistry (ICC). 52 newly-diagnosed advanced breast cancer patients were enrolled for blood samples before and/or after first-line treatment, including 24 patients who were diagnosed with HER2+ tumors and treated with anti-HER2 drugs. We enumerated CTCs and assessed levels of HER2 expression on CTCs in 2.0 ml whole blood. Enumerating CTCs at baseline could distinguish cancer patients (sensitivity, 69.2%; specificity, 100%). 80.8% (42/52) of patients had at least one CTCs before therapy. Patients with <3 CTCs at baseline had significantly longer progression-free survival (medians, 19.4 vs. 9.2 months; log-rank p = 0.046) and overall survival (medians, not yet reached; log-rank p = 0.049) than those with ≥3 CTCs. Both HER2+ and HER2-low patients could be detected with HER2 overexpression on CTCs (CTC-HER2+) (52.6%, 44.4%, respectively), whereas all the HER2-negative patients had no CTC-HER2+ phenotype. Among HER2+ patients with ≥3 CTCs at baseline, objective response only appeared in pretherapeutic CTC-HER2+ cohort (60.0%), rather than in CTC-HER2– cohort (0.0%) (p = 0.034). In conclusion, we demonstrate the significance of CTC enumeration in diagnosis and prognosis of first-line advanced breast cancer, and highlight the value of CTC-HER2 status in predicting efficacy of anti-HER2 treatment.</p

Image3_HER2 status of CTCs by peptide-functionalized nanoparticles as the diagnostic biomarker of breast cancer and predicting the efficacy of anti-HER2 treatment.TIF

Efficacy of anti-human epidermal growth factor receptor 2 (HER2) treatment is impacted by tissue-based evaluation bias due to tumor heterogeneity and dynamic changes of HER2 in breast cancer. Circulating tumor cell (CTC)-based HER2 phenotyping provides integral and real-time assessment, benefiting accurate HER2 diagnosis. This study developed a semi-quantitative fluorescent evaluation system of HER2 immunostaining on CTCs by peptide-functionalized magnetic nanoparticles (Pep@MNPs) and immunocytochemistry (ICC). 52 newly-diagnosed advanced breast cancer patients were enrolled for blood samples before and/or after first-line treatment, including 24 patients who were diagnosed with HER2+ tumors and treated with anti-HER2 drugs. We enumerated CTCs and assessed levels of HER2 expression on CTCs in 2.0 ml whole blood. Enumerating CTCs at baseline could distinguish cancer patients (sensitivity, 69.2%; specificity, 100%). 80.8% (42/52) of patients had at least one CTCs before therapy. Patients with <3 CTCs at baseline had significantly longer progression-free survival (medians, 19.4 vs. 9.2 months; log-rank p = 0.046) and overall survival (medians, not yet reached; log-rank p = 0.049) than those with ≥3 CTCs. Both HER2+ and HER2-low patients could be detected with HER2 overexpression on CTCs (CTC-HER2+) (52.6%, 44.4%, respectively), whereas all the HER2-negative patients had no CTC-HER2+ phenotype. Among HER2+ patients with ≥3 CTCs at baseline, objective response only appeared in pretherapeutic CTC-HER2+ cohort (60.0%), rather than in CTC-HER2– cohort (0.0%) (p = 0.034). In conclusion, we demonstrate the significance of CTC enumeration in diagnosis and prognosis of first-line advanced breast cancer, and highlight the value of CTC-HER2 status in predicting efficacy of anti-HER2 treatment.</p

Image1_HER2 status of CTCs by peptide-functionalized nanoparticles as the diagnostic biomarker of breast cancer and predicting the efficacy of anti-HER2 treatment.TIF

Efficacy of anti-human epidermal growth factor receptor 2 (HER2) treatment is impacted by tissue-based evaluation bias due to tumor heterogeneity and dynamic changes of HER2 in breast cancer. Circulating tumor cell (CTC)-based HER2 phenotyping provides integral and real-time assessment, benefiting accurate HER2 diagnosis. This study developed a semi-quantitative fluorescent evaluation system of HER2 immunostaining on CTCs by peptide-functionalized magnetic nanoparticles (Pep@MNPs) and immunocytochemistry (ICC). 52 newly-diagnosed advanced breast cancer patients were enrolled for blood samples before and/or after first-line treatment, including 24 patients who were diagnosed with HER2+ tumors and treated with anti-HER2 drugs. We enumerated CTCs and assessed levels of HER2 expression on CTCs in 2.0 ml whole blood. Enumerating CTCs at baseline could distinguish cancer patients (sensitivity, 69.2%; specificity, 100%). 80.8% (42/52) of patients had at least one CTCs before therapy. Patients with <3 CTCs at baseline had significantly longer progression-free survival (medians, 19.4 vs. 9.2 months; log-rank p = 0.046) and overall survival (medians, not yet reached; log-rank p = 0.049) than those with ≥3 CTCs. Both HER2+ and HER2-low patients could be detected with HER2 overexpression on CTCs (CTC-HER2+) (52.6%, 44.4%, respectively), whereas all the HER2-negative patients had no CTC-HER2+ phenotype. Among HER2+ patients with ≥3 CTCs at baseline, objective response only appeared in pretherapeutic CTC-HER2+ cohort (60.0%), rather than in CTC-HER2– cohort (0.0%) (p = 0.034). In conclusion, we demonstrate the significance of CTC enumeration in diagnosis and prognosis of first-line advanced breast cancer, and highlight the value of CTC-HER2 status in predicting efficacy of anti-HER2 treatment.</p